ArticleTherapeutic advances in gastroenterology2025

Cost-effectiveness analysis of Cadonilimab in first-line treatment of advanced HER2-negative gastric cancer or gastroesophageal junction cancer.

Kaiqi Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.